MM BIZOT PHARMA : revenue, balance sheet and financial ratios

MM BIZOT PHARMA is a French company founded 12 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75012), this company of category PME shows in 2018 a revenue of 2.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MM BIZOT PHARMA (SIREN 801071770)
Indicator 2021 2020 2018 2017 2016
Revenue N/C N/C 2 241 534 € 2 119 344 € 2 141 330 €
Net income 432 225 € 200 127 € 115 459 € 97 423 € 72 166 €
EBITDA N/C N/C 209 068 € 177 732 € 137 992 €
Net margin N/C N/C 5.2% 4.6% 3.4%

Revenue and income statement

In 2021, MM BIZOT PHARMA generates positive net income of 432 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2021: 72 k€ -> 432 k€.

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

432 225 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 140%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

140.003%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

35.579%

Asset age ratio (2021) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

0.6%

Solvency indicators evolution
MM BIZOT PHARMA

Sector positioning

Debt ratio
140.0 2021
2018
2020
2021
Q1: 29.04
Med: 85.54
Q3: 208.43
Average -14 pts over 3 years

In 2021, the debt ratio of MM BIZOT PHARMA (140.00) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
35.58% 2021
2018
2020
2021
Q1: 25.89%
Med: 44.41%
Q3: 64.18%
Average +13 pts over 3 years

In 2021, the financial autonomy of MM BIZOT PHARMA (35.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
10.73 years 2018
2018
Q1: 1.86 years
Med: 5.41 years
Q3: 9.79 years
Average

In 2018, the repayment capacity of MM BIZOT PHARMA (10.73) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 237.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

237.471

Liquidity indicators evolution
MM BIZOT PHARMA

Sector positioning

Liquidity ratio
237.47 2021
2018
2020
2021
Q1: 139.2
Med: 190.68
Q3: 259.61
Good +49 pts over 3 years

In 2021, the liquidity ratio of MM BIZOT PHARMA (237.47) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
11.61x 2018
2018
Q1: 1.93x
Med: 6.3x
Q3: 12.69x
Good

In 2018, the interest coverage of MM BIZOT PHARMA (11.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
MM BIZOT PHARMA

Positioning of MM BIZOT PHARMA in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2021, the value of MM BIZOT PHARMA is estimated at 4 957 800 € (range 3 187 890€ - 7 658 243€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2021
220 transactions
3187k€ 4957k€ 7658k€
4 957 800 € Range: 3 187 890€ - 7 658 243€
NAF 5 année 2021

Valuation method used

Net Income Multiple
432 225 € × 11.5x = 4 957 801 €
Range: 3 187 890€ - 7 658 244€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare MM BIZOT PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about MM BIZOT PHARMA

What is the revenue of MM BIZOT PHARMA ?

The revenue of MM BIZOT PHARMA in 2018 is 2.2 M€.

Is MM BIZOT PHARMA profitable?

Yes, MM BIZOT PHARMA generated a net profit of 432 k€ in 2021.

Where is the headquarters of MM BIZOT PHARMA ?

The headquarters of MM BIZOT PHARMA is located in PARIS (75012), in the department Paris.

Where to find the tax return of MM BIZOT PHARMA ?

The tax return of MM BIZOT PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MM BIZOT PHARMA operate?

MM BIZOT PHARMA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.